Inactive Instrument

Highlights MyoKardia, Inc.

Equities

MYOK

US62857M1053

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Bristol Myers Squibb : Posts 4Q Adjusted Profit, Growth for Eliquis, Opdivo	21-02-04	DJ
Bristol Myers sees up to $25 billion a year of new revenue from current drug pipeline	21-01-11	RE
Avidity Biosciences, Inc. Enters into A Research Collaboration with MyoKardia	21-01-08	CI
Bristol-Myers Squibb Company completed the acquisition of MyoKardia, Inc..	20-11-15	CI
Myokardia, Inc. Announces Results from Its Cardiac Imaging Data from 30-Week Explorer-HCM Study of Mavacamten	20-11-15	CI
MyoKardia, Inc. Presents Mavacamten Clinical and Non-Clinical Data at the American Heart Association’s Scientific Sessions 2020	20-11-13	CI
Myokardia, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-11-05	CI
Bristol Myers Squibb : MyoKardia Shares Rise After News of Bristol Myers Squibb Deal	20-10-05	DJ
MyoKardia : Bristol Myers expands heart drug business with $13 billion deal for MyoKardia	20-10-05	RE
Bristol Myers Squibb : to Pay $13.1 Billion for Heart-Drug Maker MyoKardia	20-10-05	DJ
Bristol-Myers Squibb Company entered into a definitive merger agreement to acquire MyoKardia, Inc. for $12.2 billion.	20-10-04	CI
MyoKardia, Inc. Announces First Patient Phase 2 Clinical Trial of Danicamtiv in Genetic Dilated Cardiomyopathy	20-09-09	CI
MyoKardia Presents Results from Phase 3 EXPLORER-HCM Clinical Trial of Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy	20-08-29	CI
MyoKardia, Inc. and LianBio Form Strategic Partnership to Develop and Commercialize Mavacamten Together in Greater China	20-08-11	CI
Myokardia, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-08-04	CI
MyoKardia, Inc. Doses First Patient in Phase 3 VALOR-HCM Trial of Mavacamten	20-08-03	CI
MyoKardia, Inc. Announces Receipt of Breakthrough Therapy Designation from FDA for Mavacamten for the Treatment of Symptomatic, Obstructive Hypertrophic Cardiomyopathy	20-07-23	CI
MyoKardia and Fulcrum Therapeutics Announce Multi-Target Collaboration to Discover Novel Targeted Therapies for Genetic Cardiomyopathies	20-07-21	CI
MyoKardia Announces Positive Data from Phase 2a Clinical Trial of Danicamtiv Presented at ESC’s HFA Discoveries with Simultaneous Publication in European Journal of Heart Failure	20-06-22	CI
MyoKardia, Inc. Announces Positive Topline Data from the Company’S Phase 3 Pivotal Explorer-HCM Clinical Trial of Mavacamten	20-05-11	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights MyoKardia, Inc.

Equities

MYOK

US62857M1053

Highlights

Filters